SEC filing · 8-K

Viatris Inc: Material agreement

Viatris agreed to acquire Pacira BioSciences for $36.50 per share in cash, representing an aggregate equity value of $1.65 billion.

Filed October 8, 2026

Positive for the company

What happened

On October 8, 2026, Viatris entered into a merger agreement to acquire all outstanding shares of Pacira BioSciences.

The full interpretation is in the app

Why it matters, the key numbers from the document and what to watch next: the full interpretation of every report is part of Pro.

Read the full interpretation

Read the original

Filing document on SEC.gov Press release (EX-99.1) All documents of this filing

Back to Viatris Inc

Summary generated automatically from the filing text and checked against it: every number above is printed in the document. It describes the filing and is not investment advice. Read the original before relying on it.